Trial Profile
A study to evaluate sorafenib-specific toxicities as prognostic factors in patients with advanced hepatocellular cancer treated with sorafenib
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Apr 2016
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 05 Apr 2016 New trial record